Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07180056
Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
Sponsor: Wenjin Yin
View on ClinicalTrials.gov
Summary
To evaluate the efficacy and safety of adjuvant CDK4/6 inhibitors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Official title: Efficacy and Safety of Adjuvant CDK4/6 Inhibitors in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: a Real-world Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
229
Start Date
2025-08-28
Completion Date
2033-02
Last Updated
2025-11-19
Healthy Volunteers
No
Conditions
Interventions
DRUG
CDK4/6 inhibitor
abemaciclib OR ribociclib
Locations (1)
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China